Evidence map›Paper›PMID 30456543›Full record

ReviewImmunologic research2018

Antibody-initiated beneficial and harmful immune responses.

Arpad Zsigmond Barabas, Chad Douglas Cole, Rene Lafreniere

Abstract readReview
PubMed Publisher
In one paragraph

Review in Immunologic research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Frontiers in microbiology · 2023
    Article
  3. The Role of Autophagy in Tumor Immune Infiltration in Colorectal Cancer.Analytical cellular pathology (Amsterdam) · 2022
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arpad Zsigmond BarabasDepartment of Surgery, University of Calgary, 2808 Health Sciences Centre, 3330 Hospital Dr. NW, Calgary, Alberta, T2N 4N1, Canada. barabas@ucalgary.ca.
Chad Douglas ColeDepartment of Neurosurgery, University of Utah, Salt Lake City, UT, USA.
Rene LafreniereDepartment of Surgery, University of Calgary, 2808 Health Sciences Centre, 3330 Hospital Dr. NW, Calgary, Alberta, T2N 4N1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A critical function of the immune system is to maintain tolerance to self by corrective immune responses throughout life, including preventing or correcting changes that may interfere with organ function and architectural integrity. These changes have two broad categories, namely (1) exogenous antigen-induced mishaps (e.g., due to bacterial, viral or fungal infections) and (2) endogenous antigen-caused ailments initiated by modified self-antigens derived from damaged organs following exposure to smoke, certain drugs, chemicals, infectious agents, radiation, etc., resulting in autoimmune diseases or cancer. In some cases, cells of the immune system are unable to respond with a corrective antibody response. For example, presentation of a modified self-antigen can initiate a pathogenic IgG immune response, thereby causing an autoimmune disease. Furthermore, if cancer-associated antigens are not appropriately presented to the cells of the immune system, there is failure to mount a specific pathogenic lytic IgG autoantibody response for recognition and elimination of cancer-associated antigens, and as a consequence, the cancer continues to proliferate.The third vaccination technique that we have developed and designated a modified vaccination technique (MVT) is able to correct these immunological mishaps. The premise of the MVT is that it can prevent both exogenous (infectious and contagious diseases) and endogenous (autoimmune diseases and cancer) antigen-caused diseases, as well as terminate established diseases. Therefore, by exploiting the immune system's natural abilities to make corrective responses, it has both prophylactic and therapeutic actions, with minimal side effects.

Indexed as

AnimalsAutoantibodiesAutoantigensAutoimmune DiseasesHumansImmune ToleranceImmunityNeoplasmsVaccinationAutoantibodiesAutoantigensAntibody-initiated beneficialHarmful immune responses

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.